Authors: JACQUEMIN, M.¹; RADCLIFFE, C. M.²; LAVEND'HOMME, R.¹; WORMALD, M. R.²; VANDERELST, L.¹; WALLAYS, G.³; DEWAELE, J.⁴; COLLEN, D.¹; VERMYLEN, J.¹; DWEK, R. A.²; SAINT-REMY, J-M¹; RUDD, P. M.²; DEWERCHIN, M.³

Source: Journal of Thrombosis and Haemostasis, Volume 4, Number 5, May 2006 , pp. 1047-1055(9)

Publisher: Wiley-Blackwell

Abstract:

Summary. 

Background: N-glycosylation occurs in the variable region of about 10% of antibodies but the role of carbohydrate at this location is still poorly understood. Objectives: We investigated the function of N-glycosylation in the variable region of the heavy chain of a human monoclonal antibody, mAb-LE2E9, that partially inhibits factor VIII (FVIII) activity during coagulation. Methods and results: Enzymatic deglycosylation indicated that the oligosaccharides do not determine the affinity of the antibody but enhance its FVIII neutralizing activity. A mutant antibody lacking the N-glycosylation site in the variable region of the heavy chain inhibited FVIII activity by up to 40%, while inhibition by the native antibody was 80%. To evaluate the physiological effect of such a FVIII inhibition, we investigated the ability of the mutant antibody devoid of N-glycosylation in the variable region to prevent thrombosis in mice with a strong prothombotic phenotype resulting from a type II deficiency mutation in the heparin binding site of antithrombin. Despite its moderate inhibition of FVIII activity, the mutant antibody significantly prevented thrombosis in treated animals. We also carried out glycan analysis of native and mutant antibodies. Conclusions: Modification of glycosylation in the variable region of antibodies contributes to the diversity of FVIII type II inhibition possibly by steric hindrance of the active site of FVIII by glycans, and may provide a novel strategy to modulate the functional activity of therapeutic antibodies.

Keywords: coagulation; N-glycosylation

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1538-7836.2006.01900.x

Affiliations: 1: Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium 2: Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, UK 3: Center for Transgene Technology and Gene Therapy, VIB, University of Leuven Campus, Leuven 4: Thromb-X, Leuven, Belgium

Publication date: 2006-05-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology
• By this author: JACQUEMIN, M. ;  RADCLIFFE, C. M. ;  LAVEND'HOMME, R. ;  WORMALD, M. R. ;  VANDERELST, L. ;  WALLAYS, G. ;  DEWAELE, J. ;  COLLEN, D. ;  VERMYLEN, J. ;  DWEK, R. A. ;  SAINT-REMY, J-M ;  RUDD, P. M. ;  DEWERCHIN, M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers